APOE and Alzheimer disease: Among the studies which identified APOE as a predictor, a small study by MacGowan on AD patients treated with galantamine showed that women who were APOE-ε4 non-carriers responded better to galantamine at 3 months compared to carriers (however, there were only three women in the former group), while in men it was the opposite.